+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Multiple Myeloma Drug Market - Global Forecast 2026-2032- Product Image
Multiple Myeloma Drug Market - Global Forecast 2026-2032- Product Image
New

Multiple Myeloma Drug Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 192 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968786
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior decision-makers in the pharmaceutical industry require strategic analysis to navigate the complex multiple myeloma drug market. This space is rapidly evolving amidst shifting therapeutic standards, regulatory changes, and heightened demands from both patients and payers. Informed, actionable market insights are essential for maintaining long-term competitiveness.

Market Snapshot: Multiple Myeloma Drug Market Overview

The multiple myeloma drug market grew from USD 2.44 billion in 2025 to USD 2.59 billion in 2026 and is forecasted to reach USD 3.69 billion by 2032, with a 6.05% compound annual growth rate. Market expansion is fueled by advancements in drug delivery, integration of novel therapies, and demand for improved patient outcomes that meet rigorous clinical and regulatory standards. Stakeholders—including healthcare investors, pharmaceutical strategists, and policy developers—monitor developments to align with global oncology sector trends. Timely market intelligence supports decisions regarding portfolio management and operational focus.

Scope & Segmentation

  • Drug Classes: Proteasome inhibitors, immunomodulatory agents, monoclonal antibodies, and histone deacetylase inhibitors are essential groups in current treatment protocols, allowing for flexible therapeutic combinations.
  • Lines of Therapy: From first to third-line regimens, emphasis shifts toward prolonging remission, utilizing salvage therapy, and advancing long-term management approaches.
  • Regimen Complexity: Monotherapy and combination regimens—including doublet, triplet, and quadruplet strategies—are tailored to different disease stages and patient needs.
  • Administration Routes: Intravenous, oral, and subcutaneous delivery methods support both outpatient convenience and tailored inpatient care models.
  • Patient Demographics: Segmentation by age group (sixty and above versus under sixty) and gender guides approaches that address age-related frailty, comorbidity risks, and differences in therapeutic response.
  • Distribution Channels: Hospital, online, and retail pharmacy channels influence patient access and impact commercialization strategies, necessitating considered channel partnerships.
  • Regions: The analysis covers the Americas, Europe Middle East and Africa, and Asia-Pacific, each reflecting unique regulatory requirements, reimbursement frameworks, and healthcare infrastructures.
  • Technology Use: Breakthrough treatment mechanisms, advanced delivery platforms, and supportive care tools contribute to improved patient adherence, better operational outcomes, and enriched real-world data capture.

Key Takeaways for Senior Stakeholders

  • Combination therapies exploiting differentiated mechanisms shape new treatment paradigms, with a focus on balancing survival benefits and tolerability.
  • Market evolution requires managed clinical adoption strategies, particularly as biological agents and innovative administration routes expand patient options and pose new access considerations.
  • Complicated regulatory and reimbursement processes make adaptive evidence generation essential; biomarker-driven development and continuous clinical trial optimization support responsive market entry.
  • Successful value capture depends on cross-functional alignment—portfolio development, operational execution, supply chain resilience, and payer collaboration all play critical roles in commercialization.
  • Regional policies, from health technology assessments to pricing strategies, demand localization to maximize returns and minimize access barriers.

Tariff Impact on Market Stability

Changing United States tariffs and global trade policies significantly affect oncology therapy supply chains and pricing. Adjustments in tariffs on essential ingredients and delivery components prompt manufacturers to review supplier relationships and update inventory strategies, increasing the need for targeted risk-management and periodic contract updates. Health payers respond with stricter formulary controls, while providers may alter prescribing to account for possible therapy substitutions or access changes.

Proactive Strategies for Supply Chain Resilience

  • Implement supply chain hedging, vertical integration, and establish strategic reserves to protect against tariff-driven interruptions in the multiple myeloma drug market.
  • Maintain transparent dialogue with regulators and payers on pricing and value to limit access disruptions and ensure continued care.

Methodology & Data Sources

This analysis draws from structured interviews with clinicians, regulatory officials, payers, and industry executives. Data sources include clinical trial registries, peer-reviewed research, regulatory filings, and observational studies. Policy reviews and market scenario mapping are validated through ongoing stakeholder input and systematic data checks.

Why This Report Matters

  • Links clinical shifts and commercial priorities, enabling strategic development, supply chain, and payer engagement planning across regions.
  • Clarifies the impact of tariffs and supply disruptions, supporting forward-looking risk planning in evolving market conditions.
  • Delivers actionable segmentation and regional insights necessary for effective resource allocation and robust evidence generation in the multiple myeloma drug market.

Conclusion

In this dynamic therapeutic field, synergy between clinical, operational, and market access strategies is essential for sustainable growth. The report provides a structured guide for leveraging evolving trends and responding proactively to emerging risks in global markets.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Multiple Myeloma Drug Market, by Drug Class
8.1. Histone Deacetylase Inhibitors
8.2. Immunomodulatory Agents
8.2.1. Lenalidomide
8.2.2. Pomalidomide
8.2.3. Thalidomide
8.3. Monoclonal Antibodies
8.3.1. Daratumumab
8.3.2. Elotuzumab
8.3.3. Isatuximab
8.4. Proteasome Inhibitors
8.4.1. Bortezomib
8.4.2. Carfilzomib
8.4.3. Ixazomib
9. Multiple Myeloma Drug Market, by Line Of Therapy
9.1. First Line
9.2. Second Line
9.3. Third And Beyond
10. Multiple Myeloma Drug Market, by Treatment Regimen
10.1. Combination Therapy
10.1.1. Doublet Regimen
10.1.2. Quadruplet Regimen
10.1.3. Triplet Regimen
10.2. Monotherapy
11. Multiple Myeloma Drug Market, by Route Of Administration
11.1. Intravenous
11.2. Oral
11.3. Subcutaneous
12. Multiple Myeloma Drug Market, by Patient Age
12.1. Sixty And Above
12.2. Under Sixty
13. Multiple Myeloma Drug Market, by Gender
13.1. Female
13.2. Male
14. Multiple Myeloma Drug Market, by Distribution Channel
14.1. Hospital Pharmacy
14.2. Online Pharmacy
14.3. Retail Pharmacy
15. Multiple Myeloma Drug Market, by Region
15.1. Americas
15.1.1. North America
15.1.2. Latin America
15.2. Europe, Middle East & Africa
15.2.1. Europe
15.2.2. Middle East
15.2.3. Africa
15.3. Asia-Pacific
16. Multiple Myeloma Drug Market, by Group
16.1. ASEAN
16.2. GCC
16.3. European Union
16.4. BRICS
16.5. G7
16.6. NATO
17. Multiple Myeloma Drug Market, by Country
17.1. United States
17.2. Canada
17.3. Mexico
17.4. Brazil
17.5. United Kingdom
17.6. Germany
17.7. France
17.8. Russia
17.9. Italy
17.10. Spain
17.11. China
17.12. India
17.13. Japan
17.14. Australia
17.15. South Korea
18. United States Multiple Myeloma Drug Market
19. China Multiple Myeloma Drug Market
20. Competitive Landscape
20.1. Market Concentration Analysis, 2025
20.1.1. Concentration Ratio (CR)
20.1.2. Herfindahl Hirschman Index (HHI)
20.2. Recent Developments & Impact Analysis, 2025
20.3. Product Portfolio Analysis, 2025
20.4. Benchmarking Analysis, 2025
20.5. AbbVie Inc.
20.6. Amgen Inc.
20.7. AstraZeneca Plc
20.8. Bristol-Myers Squibb Company
20.9. GlaxoSmithKline plc
20.10. Janssen Biotech, Inc.
20.11. Karyopharm Therapeutics Inc.
20.12. Novartis International AG
20.13. Sanofi S.A.
20.14. Takeda Pharmaceutical Company Limited
20.15. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL MULTIPLE MYELOMA DRUG MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL MULTIPLE MYELOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 15. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LENALIDOMIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LENALIDOMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY POMALIDOMIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY POMALIDOMIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY POMALIDOMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THALIDOMIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THALIDOMIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THALIDOMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DARATUMUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DARATUMUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DARATUMUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ELOTUZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ELOTUZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ELOTUZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ISATUXIMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ISATUXIMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ISATUXIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY BORTEZOMIB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY BORTEZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY CARFILZOMIB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY CARFILZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IXAZOMIB, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IXAZOMIB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IXAZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THIRD AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THIRD AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THIRD AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DOUBLET REGIMEN, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DOUBLET REGIMEN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DOUBLET REGIMEN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY QUADRUPLET REGIMEN, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY QUADRUPLET REGIMEN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY QUADRUPLET REGIMEN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TRIPLET REGIMEN, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TRIPLET REGIMEN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TRIPLET REGIMEN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SIXTY AND ABOVE, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SIXTY AND ABOVE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SIXTY AND ABOVE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY UNDER SIXTY, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY UNDER SIXTY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY UNDER SIXTY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FEMALE, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FEMALE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FEMALE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MALE, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MALE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MALE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 108. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 109. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 110. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 111. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 112. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 113. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 114. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 115. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 116. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 117. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 118. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 119. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 122. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 123. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 124. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 125. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 126. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 127. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 128. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 129. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 130. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 133. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 134. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 135. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 136. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 137. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 138. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 139. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 140. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 141. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 142. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 155. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 156. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 157. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 158. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 159. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 160. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 161. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 162. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 163. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 164. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 165. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 166. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 167. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 168. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 169. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 170. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 171. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 172. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 173. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 174. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 175. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 176. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 177. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 178. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 179. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 180. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 181. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 182. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 183. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 184. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 185. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 186. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 187. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 188. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 189. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 190. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 191. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 192. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 193. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 194. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 195. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 196. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 197. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 198. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 199. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 200. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 201. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 202. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 203. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 204. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 205. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 206. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 207. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 208. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 209. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 210. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 211. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 212. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 213. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 214. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 215. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 216. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 217. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 218. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 219. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 220. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 221. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 222. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 223. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 224. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 225. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 226. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 227. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 228. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 229. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 230. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 231. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 232. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 233. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 234. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 235. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 236. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 240. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 241. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 242. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 243. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 244. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 245. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 246. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 247. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 248. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 249. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 250. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 251. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 252. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 253. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 254. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 255. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 256. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 257. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 258. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 259. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 260. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 261. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 262. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 263. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 264. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 265. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 266. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 267. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 268. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 269. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 270. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 271. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 272. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 273. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 274. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 275. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 276. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 277. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 278. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 279. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 280. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 281. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 282. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 283. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 284. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 285. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 286. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 287. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 288. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 289. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 290. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 291. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 292. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 293. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 294. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 295. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 296. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 297. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 298. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 299. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 300. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Multiple Myeloma Drug market report include:
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc
  • Janssen Biotech, Inc.
  • Karyopharm Therapeutics Inc.
  • Novartis International AG
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages192
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.59 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.69 Billion
Compound Annual Growth Rate6.0%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Topics

Related Reports

Multiple Myeloma Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Multiple Myeloma Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 98 Pages
  • Global
From
Multiple Myeloma Drugs Market Report 2025 - Product Image

Multiple Myeloma Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Multiple Myeloma Drugs Market Size, Share, Trends and Forecast by Therapy, Drug Type, End User, Distribution Channel, and Region, 2025-2033 - Product Image

Multiple Myeloma Drugs Market Size, Share, Trends and Forecast by Therapy, Drug Type, End User, Distribution Channel, and Region, 2025-2033

  • Report
  • 119 Pages
  • Global
From
Multiple Myeloma Therapeutics - Global Strategic Business Report - Product Image

Multiple Myeloma Therapeutics - Global Strategic Business Report

  • Report
  • 293 Pages
  • Global
From
Multiple Myeloma Drugs Market - Global Strategic Business Report - Product Image

Multiple Myeloma Drugs Market - Global Strategic Business Report

  • Report
  • 274 Pages
  • Global
From

About the Multiple Myeloma Drug Market

Multiple Myeloma is a type of cancer that affects the plasma cells in the bone marrow. It is a form of Leukemia, and is the second most common type of blood cancer. Treatment for Multiple Myeloma typically involves a combination of chemotherapy, radiation therapy, and targeted drug therapy. The Multiple Myeloma drug market is composed of a variety of drugs, including proteasome inhibitors, immunomodulatory agents, monoclonal antibodies, and other targeted therapies. These drugs are used to treat the disease, as well as to reduce the risk of relapse. The Multiple Myeloma drug market is highly competitive, with many companies offering a range of treatments. Some of the major players in the market include Bristol-Myers Squibb, Celgene, Novartis, Amgen, and Johnson & Johnson. Other companies such as Merck, Pfizer, and Takeda are also active in the market. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.